125 related articles for article (PubMed ID: 30800222)
1. The correlation of p22
Kobayashi M; Saito R; Miki Y; Nanamiya R; Inoue C; Abe J; Sato I; Okada Y; Sasano H
Oncotarget; 2019 Feb; 10(10):1119-1131. PubMed ID: 30800222
[TBL] [Abstract][Full Text] [Related]
2. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
Front Oncol; 2020; 10():542007. PubMed ID: 33123465
[No Abstract] [Full Text] [Related]
3. NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer.
Li Q; Fu GB; Zheng JT; He J; Niu XB; Chen QD; Yin Y; Qian X; Xu Q; Wang M; Sun AF; Shu Y; Rui H; Liu LZ; Jiang BH
Biochim Biophys Acta; 2013 Dec; 1833(12):3375-3385. PubMed ID: 24113386
[TBL] [Abstract][Full Text] [Related]
4. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
5. The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma.
Wang Y; Lian H; Li J; Zhao M; Hao Z; Zheng X; Zhao L; Cui J
J Invest Surg; 2024 Dec; 37(1):2301081. PubMed ID: 38224012
[TBL] [Abstract][Full Text] [Related]
6. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
7. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
9. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.
Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L
Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p22
Li Q; Feng X; Niu F; Yang J; Xu Y; Pu X; Chen J; Fan X; Jiang B; Huang Q
J Cancer; 2021; 12(14):4277-4287. PubMed ID: 34093828
[TBL] [Abstract][Full Text] [Related]
12. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
13. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
14. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase.
Görlach A; Diebold I; Schini-Kerth VB; Berchner-Pfannschmidt U; Roth U; Brandes RP; Kietzmann T; Busse R
Circ Res; 2001 Jul; 89(1):47-54. PubMed ID: 11440977
[TBL] [Abstract][Full Text] [Related]
15. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
Zhang L; Wu H; Zhang Y; Xiao X; Chu F; Zhang L
Bioengineered; 2022 Jan; 13(1):950-962. PubMed ID: 34969360
[TBL] [Abstract][Full Text] [Related]
16. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
17. GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells.
Zhou QY; Tu CY; Shao CX; Wang WK; Zhu JD; Cai Y; Mao JY; Chen W
Am J Transl Res; 2017; 9(5):2608-2617. PubMed ID: 28560008
[TBL] [Abstract][Full Text] [Related]
18. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor 1α-induced epithelial-mesenchymal transition of endometrial epithelial cells may contribute to the development of endometriosis.
Xiong Y; Liu Y; Xiong W; Zhang L; Liu H; Du Y; Li N
Hum Reprod; 2016 Jun; 31(6):1327-38. PubMed ID: 27094478
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
